Medical inquiries

Connect with my medical science liaison

Chat live

Available Monday - Friday 9AM - 4:30PM ET

Call me now

Available Monday - Friday 9AM - 7:30PM ET

Email your inquiry

Call 1-800-526-7736

Available Monday - Friday 9AM - 8PM ET

Live video

Available Monday - Friday 9AM - 4:30PM ET

This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.

TREMFYA® (guselkumab)

Medical Information

+ Save link

TREMFYA – Switching from TREMFYA to Other Biologics in Crohn's Disease or Ulcerative Colitis

Last Updated: 09/13/2024

SUMMARY

The company cannot recommend any practices, procedures, or usage that deviate from the approved labeling.
The phase 3 clinical trial program of TREMFYA in the treatment of adults with moderately to severely active Crohn's disease or ulcerative colitis did not evaluate the switching of TREMFYA to other biologics.¹^,²

LITERATURE SEARCH

A literature search of MEDLINE^®, EMBASE^®, BIOSIS Previews^®, and DERWENT^® (and/or other resources, including internal/external databases) was conducted on 27 June 2024.

References

Show

1	Janssen Research & Development, LLC. A study of the efficacy and safety of guselkumab in participants with moderately to severely active Crohn’s disease (GALAXI). In: Clinical Trials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2024 June 28]. Available from: https://clinicaltrials.gov/ct2/show/NCT03466411. NLM Identifier: NCT03466411.
2	Janssen Research & Development, LLC. A study of guselkumab in participants with moderately to severely active ulcerative colitis (QUASAR). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000 - [cited 2024 July 08]. Available from: https://clinicaltrials.gov/ct2/show/NCT04033445. NLM Identifier: NCT04033445.